Castle Biosciences, Inc. (CSTL) Financial Analysis & Valuation | Quarter Chart
Castle Biosciences, Inc. (CSTL)
CSTLPrice: $25.27
Fair Value: 🔒
🔒score
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed wi... more
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and ... more
Description
Shares
| Market Cap | $751.31M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Derek J. Maetzold |
| IPO Date | 2019-07-25 | CAGR | 0.5% |
| Employees | 784 | Website | castlebiosciences.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CSTL chart loading...
Fundamentals
Technicals
| Enterprise Value | $949.44M | P/E Ratio | -30.45 |
| Forward P/E | -45.28 | PEG Ratio | — |
| P/S Ratio | 0.3 | P/B Ratio | 0.23 |
| P/CF Ratio | 1.63 | P/FCF Ratio | 3.71 |
| EPS | $-0.83 | EPS Growth 1Y | -237.27% |
| EPS Growth 3Y | -67.2% | EPS Growth 5Y | 66.12% |
| Revenue Growth 1Y | 3.66% | Gross Margin | 0.59% |
| Operating Margin | -0.12% | Profit Margin | -0.07% |
| ROE | -0.05% | ROA | -0.04% |
| ROCE | -0.08% | Current Ratio | 5.26 |
| Quick Ratio | 5.11 | Cash Ratio | 1.7 |
| Debt/Equity | 0.08 | Interest Coverage | -1126.58 |
| Altman Z Score | 5.05 | Piotroski Score | 2 |